Loading
A phase 1/2 trial of Dual-target CAR-NK cells in non-small-cell lung cancer, run by Beijing Biotech, now recruiting.
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC is a phase 1/2 interventional study registered as NCT07467863 by Beijing Biotech, with 48 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: Dual-target CAR-NK cells and Lymphodepleting chemotherapy.
Shares Mesothelin, EGFR, HER2, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, HER2, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, HER2, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.